



# Amgen Canada

Amgen applies science and innovation to help fight serious illness and dramatically improve people's lives. With Canadian headquarters located in Mississauga's vibrant biomedical cluster, and a research facility in Burnaby, British Columbia, Amgen's Canadian affiliate has been an important contributor to Canada's biotechnology sector since 1991.

Amgen Canada serves patients throughout Canada by delivering vital medicines to them. In addition, Amgen contributes to the development of new therapies or new uses for existing medicines in partnership with many of Canada's leading healthcare, academic, research, government and patient organizations. Today, tens of thousands of Canadians use Amgen medicines every year, and thousands more are enrolling in Amgen clinical studies that deliver the next generation of innovation.

## Commitment to Improve Canada's Healthcare System

As a global leader in developing and delivering breakthrough biologic medicines that improve the health and well-being of patients dealing with serious illnesses, Amgen is committed to working with Canada's federal and provincial governments and other stakeholders to develop practical, cost-effective and long-term ways to sustain and improve Canada's healthcare system. Biologic medicines have the ability to change the practice of medicine like never before, and Amgen welcomes the opportunity to work together with patients, doctors, industry, healthcare practitioners and government to find healthcare solutions that are in the best interests of all Canadians.

## An Integral Part of the Canadian Economy

Amgen Canada understands the importance of its operations to the continuing growth and success of the bioscience industries in Canada. The company's efforts in clinical operations, sales and marketing and other areas play a part in strengthening the Greater Toronto Area biotechnology cluster of companies, government and educational institutions and in growing Canada's leadership in biotechnology. As the region's biosciences sector has grown, Amgen has grown its own business in Canada, creating over 400 new jobs and introducing innovative medicines to Canadian healthcare providers and patients.

Amgen British Columbia, one of several research facilities operated by Amgen, specializes in the discovery and development of human therapeutic antibodies. The research center, located in Burnaby, became part of Amgen with the acquisition of Abgenix Inc. in April 2006. It currently employs over 50 people, including research scientists and support staff.

### QUICK FACTS

**Locations**  
 Mississauga, Ontario  
 Burnaby, British Columbia

**Staff**  
 Burnaby – Approx. 50  
 Mississauga – Approx. 200  
 Field employees across the country – Approx. 150

**Key Functions**

*Burnaby*

- Research and Development

*Mississauga*

- Scientific Affairs
- Commercial Operations
- Administrative Functions

**Address/Phone**  
 Amgen Canada  
 6775 Financial Drive  
 Mississauga, Ontario  
 Canada L5N 0A4  
 (800) 665-4273

Amgen British Columbia  
 7990 Enterprise Street  
 Burnaby, British Columbia  
 Canada V5A 1V7  
 (604) 676-8300

### HISTORY IN CANADA

- 1991 – Amgen Canada founded in Mississauga
- 1992 – Launch of NEUPOGEN®
- 1999 – Launch of STEMGEN®
- 2002 – Launches of Aranesp® and Kineret®, Amgen acquires Immunex, including Enbrel®
- 2004 – Launch of Neulasta® and Sensipar®
- 2005 – Kepivance® approved for use in Canada
- 2006 – Amgen acquires Abgenix, Inc., including its Burnaby R&D group
- 2008 – Launch of Vectibix®
- 2009 – Launch of Nplate®
- 2010 – Launch of Prolia®
- 2011 – Launch of XGEVA™

## ILLUSTRATIVE LIST OF AMGEN CANADA PARTNERS

### Inflammation

- Alliance for a Canadian Arthritis Program
- Arthritis Society (regional and national)
- Canadian Rheumatology Research Consortium
- Canadian Dermatology Association
- Canadian Skin Patient Alliance

### Nephrology

- Canadian Society of Nephrology
- Kidney Foundation of Canada (regional and national)
- Canadian Association of Nephrology Nurses
- Research chairs, professorships and partnerships (such as at Université Laval, Ottawa Hospital Kidney Research Centre, University Health Network, Toronto, and McMaster University/St. Joseph's Health Care, Hamilton)

### Oncology

- Canadian Assoc. of Nurses of Oncology
- Canadian Bone Marrow Transplant Group
- Lymphoma Foundation
- Ontario Cancer Research Network
- Colorectal Cancer Association of Canada
- The Campaign to Control Cancer
- The Cancer Advocacy Coalition

### Bone Health

- Osteoporosis Canada
- SIGMA Canadian Menopause Society
- CARP (Canadian Association of Retired Persons)
- Society of Obstetricians and Gynaecologists of Canada

### ABOUT AMGEN

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit [www.amgen.ca](http://www.amgen.ca).

## Amgen Medicines Available in Canada

**Aranesp®** (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic kidney disease. It is also prescribed for the treatment of anemia in patients with non-myeloid malignancies, where anemia is due to the effect of concomitantly administered chemotherapy.

**Enbrel®** (etanercept) is indicated for the treatment of moderately-to-severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis (arthritis of the spine) and chronic moderate to severe plaque psoriasis.

**Neulasta®** (pegfilgrastim) or **NEUPOGEN®** (filgrastim) is indicated to reduce the incidence of infection (initially marked by a low white blood cell count and fever) in certain cancer patients who are receiving chemotherapy that could decrease their number of infection-fighting white blood cells. Neulasta® is a longer-acting form of NEUPOGEN® that requires only one injection per chemotherapy cycle.

**Sensipar®** (cinacalcet HCl) is an oral therapy prescribed to treat hyperparathyroidism caused by chronic kidney disease; it is approved for use in patients with chronic kidney disease receiving dialysis.

**Vectibix®** (panitumumab) is indicated as monotherapy for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

**Nplate®** (romiplostim) is the first and only platelet producer approved in Canada for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

**Prolia®** (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral and hip fractures.

**XGEVA™** (denosumab) is indicated for reducing the risk of developing skeletal-related events (SREs) in adults with bone metastases from solid tumours. XGEVA is not indicated for reducing the risk of skeletal-related events in patients with multiple myeloma.

## Clinical Trials

Amgen Canada conducts significant numbers of clinical trials with leading academic research institutions, hospitals, and clinics throughout Canada. Amgen Canada's Development Operations team, working with colleagues around the world, participates in Amgen global clinical programs spanning phases 1-4 in nephrology, oncology, hematology, inflammation, bone health, cardiology, and metabolic disorders. Since 1991, more than 10,000 patients have enrolled in Amgen clinical trials in Canada. Currently some 2,000 Canadian patients are enrolled in more than 60 trials at about 500 centres across Canada. Those centres include major teaching hospitals as well as community-based sites. A complete list of Amgen's clinical trials can be found on [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

## Community Involvement

Amgen is proud to contribute to many philanthropic efforts at academic institutions, in hospitals, with patients and in the community. Amgen is committed to raising the value of science literacy in the community; attracting bright young minds into the field of science by helping educators to teach more effectively; and improving access to science resources for teachers, students and the community at large. Amgen also dedicates substantial resources to strengthen and enrich the community. Holding Hands, Amgen Canada's community philanthropy initiative, defines the core focus of the company's community involvement - to support programs that help bring local families in need closer to wellness as they navigate a complex healthcare system, through information, education and support.

The company supports nephrology research in Canada through a variety of fellowships and research chairs and funds research activities in rheumatoid arthritis, osteoporosis and related diseases, including the Canadian Arthritis Society Fellowship in Rheumatoid Arthritis. Amgen Canada also supports the Kidney Foundation of Canada's KRESCENT (Kidney Research Scientist Core Education and National Training) Program, which recruits and trains world-class kidney scientists in Canada. In cancer care, Amgen Canada supports education initiatives at the Lymphoma Foundation Canada, the Colorectal Cancer Association and Wellspring.

**AMGEN**